Related Experiment Video

Updated: Jun 8, 2026

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

Comparative study of skin permeation profiles between brand and generic tulobuterol patches

Shigemi Yoshihara1, Hironobu Fukuda, Toshio Abe

  • 1Department of Pediatrics, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi321–0293, Japan. shigemi@dokkyomed.ac.jp

Biological & Pharmaceutical Bulletin
|October 9, 2010
PubMed

Insights

Generic tulobuterol patches show higher skin penetration than brand-name versions in a rat model. This highlights the importance of considering skin condition alongside asthma control when selecting tulobuterol patches.

Area of Science:

  • Pharmacology
  • Dermatology
  • Pediatrics

Background:

  • Tulobuterol patches are long-acting bronchodilators for managing pediatric asthma.
  • Pediatric asthma patients frequently have atopic dermatitis, characterized by impaired skin barrier function.

Purpose of the Study:

  • To compare the skin penetration profiles of brand-name and generic tulobuterol patches.
  • To evaluate the impact of skin barrier impairment on tulobuterol patch absorption.

Main Methods:

  • Utilized a rat model with an impaired skin barrier.
  • Assessed and compared skin penetration of tulobuterol from brand and generic patches.

Main Results:

  • Generic tulobuterol patches demonstrated significantly higher skin penetration compared to the brand-name patch (p<0.001).
  • Skin barrier impairment influenced the absorption rate of tulobuterol.

Conclusions:

  • Pharmaceutical properties of tulobuterol patches vary between generic and brand-name products.
  • Careful consideration of both asthma control and skin condition is crucial when prescribing tulobuterol patches for pediatric patients.

More Related Videos

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...